Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 7/20 | 0.61 |
| ▸ | MTNR1A | P48039 | 9/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 3/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649521 | 1.00 | ACACB (0.61) | ACACBMTNR1AMTNR1BNQO2ACACA | |
| SCHEMBL649221 | 1.00 | ACACB (0.61) | ACACBMTNR1AMTNR1BNQO2ACACA | |
| SCHEMBL649561 | 0.93 | ACACB (0.52) | ACACBMTNR1AMTNR1BNQO2 | |
| SCHEMBL649560 | 0.93 | ACACB (0.52) | ACACBMTNR1AMTNR1BNQO2 | |
| SCHEMBL648433 | 0.92 | ACACB (0.61) | ACACBMTNR1AMTNR1BNQO2ACACA | |
| SCHEMBL648434 | 0.92 | ACACB (0.61) | ACACBMTNR1AMTNR1BNQO2ACACA | |
| SCHEMBL649910 | 0.91 | ACACB (0.60) | ACACBMTNR1AMTNR1BNQO2ACACA | |
| SCHEMBL649444 | 0.91 | ACACB (0.60) | ACACBMTNR1AMTNR1BNQO2ACACA | |
| SCHEMBL650375 | 0.90 | ACACB (0.59) | ACACBMTNR1AMTNR1BNQO2ACACA | |
| SCHEMBL649154 | 0.90 | ACACB (0.59) | ACACBMTNR1AMTNR1BNQO2ACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109732-A1 | LIPID AMINES | MODERNATX INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-3879295-B1 | CELLULAR POSITIONING BASED VERIFICATION OF AN ESTIMATED VEHICLE POSITION | MAGNA ELECTRONICS SWEDEN AB (SE) | 2025-06-25 | — | — | EP | claimed |
| EP-4315966-A1 | METHODS FOR IMPROVED FEDERATED MACHINE LEARNING IN WIRELESS NETWORKS | Telefonaktiebolaget LM Ericsson (publ) (SE) | 2024-02-07 | — | — | EP | claimed |
| WO-2022199824-A1 | METHODS FOR IMPROVED FEDERATED MACHINE LEARNING IN WIRELESS NETWORKS | TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (SE) | 2022-09-29 | — | — | WO | claimed |
| EP-2545914-A1 | 2-amino-2-oxoethyl trans-3-[5-(6-methoxy-naphtalen-1-yl)-1,3-dioxan-2-yl]propyl-carbamate for use in the treatment of persistent cancer pain | SANOFI (FR) | 2013-01-16 | — | — | EP | claimed |
| EP-2545915-A1 | 2-amino-2-oxoethyl trans-3-[5-(6-methoxy-naphtalen-1-yl)-1,3-dioxan-2-yl]propyl-carbamate for use in the treatment of persistent cancer pain | SANOFI (FR) | 2013-01-16 | — | — | EP | claimed |
| US-8119687-B2 | Derivatives of dioxan-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | SANOFI-AVENTIS (FR) | 2012-02-21 | — | — | US | claimed |
| US-20100280076-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-11-04 | — | — | US | claimed |
| US-20090286868-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-11-19 | — | — | US | claimed |
| EP-1537096-B1 | DERIVATIVES OF DIOXANE-2-ALKYL CARBAMATES, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2008-09-24 | — | — | EP | claimed |
| US-20060247290-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2006-11-02 | — | — | US | claimed |
| US-7119116-B2 | Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | SANOFI-AVENTIS (FR) | 2006-10-10 | — | — | US | claimed |
| US-20050182130-A1 | Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | SANOFI AVENTIS (FR) | 2005-08-18 | — | — | US | claimed |
| US-12628224-B2 | Methods for improved federated machine learning in wireless networks | TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (SE) | 2026-05-12 | — | — | US | disclosed |
| US-20260109732-A1 | LIPID AMINES | MODERNATX INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12591111-B2 | Optical imaging system | SAMSUNG ELECTRO-MECHANICS CO., LTD. (KR) | 2026-03-31 | — | — | US | disclosed |
| US-20090286868-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-11-19 | — | — | US | disclosed |
| US-20060247290-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2006-11-02 | — | — | US | disclosed |
| US-7119116-B2 | Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | SANOFI-AVENTIS (FR) | 2006-10-10 | — | — | US | disclosed |
| US-20050182130-A1 | Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | SANOFI AVENTIS (FR) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280076-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | CHRM3, CHRM2, CHRM4 | ACACB 829/4885MTNR1A 466/4885MTNR1B 1041/4885 |
| US-20060247290-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | CHRM3, CHRM2, CHRM4 | ACACB 829/4885MTNR1A 466/4885MTNR1B 1041/4885 |
| US-20050182130-A1 | Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | CHRM3, CHRM2, CHRM4 | ACACB 681/4885MTNR1A 540/4885MTNR1B 1234/4885 |
| US-12591111-B2 | Optical imaging system | VCL, LGALS8, LAGE3 | ACACB 4448/4885MTNR1A 3744/4885MTNR1B 4109/4885 |
| US-20090286868-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | CHRM3, CHRM2, CHRM4 | ACACB 829/4885MTNR1A 466/4885MTNR1B 1041/4885 |
| US-20260109732-A1 | LIPID AMINES | LDLR, NPC1, PHOSPHO1 | ACACB 991/4885MTNR1A 520/4885MTNR1B 639/4885 |
| US-12628224-B2 | Methods for improved federated machine learning in wireless networks | LRRFIP1, RXFP3, RXFP4 | ACACB 1500/4885MTNR1A 1696/4885MTNR1B 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.